Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT03377101
What this trial is testing

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor Positive+1 more
National Cancer Institute (NCI)
Not applicableStudy completedNCT05173103
What this trial is testing

Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
University of Milano Bicocca 254
Testing effectiveness (Phase 2)Study completedNCT02871791
What this trial is testing

Palbociclib With Everolimus + Exemestane In BC

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor (HR)-Positive Breast Cancer
Dana-Farber Cancer Institute 41
Testing effectiveness (Phase 2)Study completedNCT02028364
What this trial is testing

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

Who this might be right for
Breast Cancer
Jules Bordet Institute 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07102940
What this trial is testing

Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

Who this might be right for
Breast CancerHER 2 Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+1 more
George Washington University 50
Testing effectiveness (Phase 2)Looking for participantsNCT05868226
What this trial is testing

PRE-ISPY Phase I/II Oncology Platform Program

Who this might be right for
HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more
QuantumLeap Healthcare Collaborative 280
Early research (Phase 1)Ended earlyNCT06878248
What this trial is testing

Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer MetastaticLocally Advanced Breast Cancer (LABC)Malignant Neoplasm of Breast+3 more
Calibr, a division of Scripps Research 10
Early research (Phase 1)Study completedNCT03251378
What this trial is testing

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Who this might be right for
Advanced Solid TumorsMetastatic Colon CancerMetastatic Breast Cancer+4 more
Hutchison Medipharma Limited 129
Testing effectiveness (Phase 2)Looking for participantsNCT04923542
What this trial is testing

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

Who this might be right for
Brain MetastasesHR+ Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 31
Not applicableStudy completedNCT06676436
What this trial is testing

Observational Study on the Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Cancer
AstraZeneca 204
Not applicableStudy completedNCT04460898
What this trial is testing

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

Who this might be right for
Breast Cancer
Pfizer 195
Large-scale testing (Phase 3)Active Not RecruitingNCT03820830
What this trial is testing

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Who this might be right for
Breast Cancer Recurrent
ETOP IBCSG Partners Foundation 405
Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 124
Large-scale testing (Phase 3)Looking for participantsNCT04263298
What this trial is testing

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Herui Yao 210
Not applicableStudy completedNCT04524728
What this trial is testing

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Who this might be right for
BreastNeoplasm MalignantFemale
Istituti Clinici Scientifici Maugeri SpA 191
Testing effectiveness (Phase 2)Looking for participantsNCT07396324
What this trial is testing

Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

Who this might be right for
HR-positive/HER2-negative Breast Cancer
RenJi Hospital 55
Large-scale testing (Phase 3)Ended earlyNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Early research (Phase 1)Looking for participantsNCT05304962
What this trial is testing

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Regor Pharmaceuticals Inc. 64
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07748208
What this trial is testing

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

Who this might be right for
Breast CancerDiabetes Type II
Hoffmann-La Roche 40
Large-scale testing (Phase 3)Active Not RecruitingNCT01674140
What this trial is testing

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 1,939
Next Page